Allianz SE Takes Position in Johnson & Johnson (NYSE:JNJ)

Allianz SE purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 132,677 shares of the company's stock, valued at approximately $19,020,000.

Several other institutional investors have also made changes to their positions in JNJ. IFS Advisors LLC lifted its holdings in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares during the period. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $29,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $32,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in Johnson & Johnson in the fourth quarter valued at about $38,000. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Monday, March 10th. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 19th. Bank of America raised their price objective on Johnson & Johnson from $159.00 to $171.00 and gave the company a "neutral" rating in a report on Wednesday, March 5th. Finally, Raymond James dropped their target price on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $171.33.

Johnson & Johnson Stock Up 1.3 %

Shares of Johnson & Johnson stock traded up $2.18 during trading on Monday, reaching $165.89. 7,156,737 shares of the company traded hands, compared to its average volume of 7,644,531. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market capitalization of $399.76 billion, a PE ratio of 24.95, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a 50 day moving average price of $158.68 and a 200-day moving average price of $156.07. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. The business's revenue was up 5.3% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson's payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.